TY - JOUR
T1 - EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer
T2 - Analysis of data from the phase 3 FLEX study
AU - Pirker, Robert
AU - Pereira, Jose R.
AU - Von Pawel, Joachim
AU - Krzakowski, Maciej
AU - Ramlau, Rodryg
AU - Park, Keunchil
AU - De Marinis, Filippo
AU - Eberhardt, Wilfried E E
AU - Paz-Ares, Luis
AU - Störkel, Stephan
AU - Schumacher, Karl Maria
AU - Von Heydebreck, Anja
AU - Celik, Ilhan
AU - O'Byrne, Kenneth J.
PY - 2012/1
Y1 - 2012/1
N2 - Background: Findings from the phase 3 First-Line ErbituX in lung cancer (FLEX) study showed that the addition of cetuximab to first-line chemotherapy significantly improved overall survival compared with chemotherapy alone (hazard ratio [HR] 0·871, 95% CI 0·762-0·996; p=0·044) in patients with advanced non-small-cell lung cancer (NSCLC). To define patients benefiting most from cetuximab, we studied the association of tumour EGFR expression level with clinical outcome in FLEX study patients. Methods: We used prospectively collected tumour EGFR expression data to generate an immunohistochemistry score for FLEX study patients on a continuous scale of 0-300. We used response data to select an outcome-based discriminatory threshold immunohistochemistry score for EGFR expression of 200. Treatment outcome was analysed in patients with low (immunohistochemistry score
AB - Background: Findings from the phase 3 First-Line ErbituX in lung cancer (FLEX) study showed that the addition of cetuximab to first-line chemotherapy significantly improved overall survival compared with chemotherapy alone (hazard ratio [HR] 0·871, 95% CI 0·762-0·996; p=0·044) in patients with advanced non-small-cell lung cancer (NSCLC). To define patients benefiting most from cetuximab, we studied the association of tumour EGFR expression level with clinical outcome in FLEX study patients. Methods: We used prospectively collected tumour EGFR expression data to generate an immunohistochemistry score for FLEX study patients on a continuous scale of 0-300. We used response data to select an outcome-based discriminatory threshold immunohistochemistry score for EGFR expression of 200. Treatment outcome was analysed in patients with low (immunohistochemistry score
UR - http://www.scopus.com/inward/record.url?scp=84855311144&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855311144&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(11)70318-7
DO - 10.1016/S1470-2045(11)70318-7
M3 - Article
C2 - 22056021
AN - SCOPUS:84855311144
VL - 13
SP - 33
EP - 42
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 1
ER -